PL2139484T3 - Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha - Google Patents

Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Info

Publication number
PL2139484T3
PL2139484T3 PL08742677T PL08742677T PL2139484T3 PL 2139484 T3 PL2139484 T3 PL 2139484T3 PL 08742677 T PL08742677 T PL 08742677T PL 08742677 T PL08742677 T PL 08742677T PL 2139484 T3 PL2139484 T3 PL 2139484T3
Authority
PL
Poland
Prior art keywords
methods
treating cancer
pi3k alpha
pyridopyrimidinone
inhibitors
Prior art date
Application number
PL08742677T
Other languages
Polish (pl)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PL2139484T3 publication Critical patent/PL2139484T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08742677T 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha PL2139484T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
PCT/US2008/004573 WO2008124161A1 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
EP08742677.1A EP2139484B9 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Publications (1)

Publication Number Publication Date
PL2139484T3 true PL2139484T3 (en) 2013-12-31

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08742677T PL2139484T3 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Country Status (31)

Country Link
US (1) US8513266B2 (en)
EP (1) EP2139484B9 (en)
JP (3) JP2010523670A (en)
KR (1) KR101626435B1 (en)
CN (2) CN101715345A (en)
AU (1) AU2008236562B2 (en)
BR (1) BRPI0810206A2 (en)
CA (1) CA2683641C (en)
CO (1) CO6251254A2 (en)
CR (1) CR11100A (en)
DK (1) DK2139484T3 (en)
DO (1) DOP2009000243A (en)
EA (1) EA020022B1 (en)
EC (1) ECSP099724A (en)
ES (1) ES2430614T3 (en)
HN (1) HN2009003002A (en)
HR (1) HRP20130688T1 (en)
IL (1) IL201284A (en)
MA (1) MA31358B1 (en)
ME (1) ME00936B (en)
MX (1) MX2009010930A (en)
MY (1) MY150697A (en)
NZ (1) NZ580110A (en)
PL (1) PL2139484T3 (en)
PT (1) PT2139484E (en)
RS (1) RS52939B (en)
SI (1) SI2139484T1 (en)
TN (1) TN2009000400A1 (en)
UA (1) UA100979C2 (en)
WO (1) WO2008124161A1 (en)
ZA (1) ZA200906764B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
JP5461012B2 (en) * 2005-10-07 2014-04-02 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
CN101282948A (en) * 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (en) * 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
DK2139484T3 (en) 2007-04-10 2013-10-21 Exelixis Inc Methods for Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K-alpha
NZ580009A (en) * 2007-04-11 2012-06-29 Exelixis Inc Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (en) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ethynyl-substituted pyridine and pyrimidine derivatives and their use in the treatment of viral infections
AR072939A1 (en) 2008-08-20 2010-09-29 Schering Corp DERIVATIVES OF PIRIDINE AND PYRIMIDINE REPLACED WITH ETHYLENE AND ITS USE IN THE TREATMENT OF VIRAL INFECTIONS
AU2009282567B2 (en) 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR080151A1 (en) 2010-02-09 2012-03-14 Exelixis Inc METHODS TO TREAT CANCER USING PI 3K PYRIDOPIRIMIDINONE INHIBITORS AND MTOR IN COMBINATION WITH AUTOPHAGIA INHIBITORS
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
TWI642670B (en) 2010-09-14 2018-12-01 伊塞利克斯公司 PI3K-delta inhibitor and its application and production method
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
US9441013B2 (en) * 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (en) * 2011-06-15 2013-02-16 Exelixis Inc Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab
RU2014107713A (en) * 2011-07-28 2015-09-10 Дженентек, Инк BREAST CANCER MODEL IN ANIMALS, EXCEPT HUMAN, WITH ACTIVATED PIK3CA H1047R
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
CN104302294A (en) 2011-11-01 2015-01-21 埃克塞利希斯股份有限公司 N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinone as a phosphatidylinositol 3-kinase inhibitor for the treatment of lymphoproliferative malignancies Oxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide
US9682141B2 (en) 2011-11-11 2017-06-20 Intellikine Llc Combination of kinase inhibitors and uses thereof
CA2860051A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
SI2882440T1 (en) 2012-08-07 2019-05-31 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR102793563B1 (en) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 Preparation and composition for treatment of malignant tumors
RS61934B1 (en) * 2016-08-15 2021-07-30 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP7027699B2 (en) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 Tire tread and tires
KR102708050B1 (en) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. Combination therapy for the treatment of mastocytosis
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
EP4353222A1 (en) 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
TWI878335B (en) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
JP7677646B2 (en) * 2019-12-10 2025-05-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー Replication protein A (RPA)-DNA interaction inhibitors
CN115243681B (en) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
FI4084778T3 (en) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USING THEM
KR102195221B1 (en) 2019-12-31 2020-12-24 서울대학교산학협력단 Pharmaceutical composition for combination of radiotherapy for treating triple negative breast cancer comprising phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 inhibitor
CN111358952B (en) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） A kind of antitumor drug composition and its preparation and application
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
CA2491191C (en) * 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
BRPI0507852A (en) * 2004-02-18 2007-07-10 Warner Lambert Co 2- (pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-ones
ES2292130T3 (en) 2004-05-04 2008-03-01 Warner-Lambert Company Llc PIRIDO (2,3-D) PIRIMIDIN-7-PIRROLIL-SUBSTITUTED WAVES AND DERIVED FROM THEMSELVES AS THERAPEUTIC AGENTS.
JP5216958B2 (en) * 2005-07-06 2013-06-19 株式会社三和技術総合研究所 Leakage current detection device and leakage current detection method
JP5461012B2 (en) 2005-10-07 2014-04-02 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
CN101282948A (en) * 2005-10-07 2008-10-08 埃克塞里艾克西斯公司 N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1931670B1 (en) * 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ATE514695T1 (en) * 2006-09-15 2011-07-15 Pfizer Prod Inc PYRIDO(2,3-D)PYRIMIDINONE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS
DK2139484T3 (en) 2007-04-10 2013-10-21 Exelixis Inc Methods for Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K-alpha
CA2683784A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
JP2010523681A (en) 2007-04-11 2010-07-15 エクセリクシス， インク． Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-α for the treatment of cancer
NZ580009A (en) * 2007-04-11 2012-06-29 Exelixis Inc Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
EP2350070A1 (en) * 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor

Also Published As

Publication number Publication date
RS52939B (en) 2014-02-28
UA100979C2 (en) 2013-02-25
AU2008236562B2 (en) 2013-11-07
CN102727498A (en) 2012-10-17
MY150697A (en) 2014-02-28
SI2139484T1 (en) 2013-10-30
MX2009010930A (en) 2010-01-20
IL201284A0 (en) 2010-05-31
EP2139484B9 (en) 2014-06-11
HRP20130688T1 (en) 2013-09-30
TN2009000400A1 (en) 2010-12-31
CN101715345A (en) 2010-05-26
AU2008236562A1 (en) 2008-10-16
EP2139484B8 (en) 2013-08-21
EA200970932A1 (en) 2010-04-30
CN102727498B (en) 2016-08-03
EA020022B1 (en) 2014-08-29
KR20100016354A (en) 2010-02-12
KR101626435B1 (en) 2016-06-01
US8513266B2 (en) 2013-08-20
ME00936B (en) 2012-06-20
CA2683641A1 (en) 2008-10-16
JP2014139217A (en) 2014-07-31
CA2683641C (en) 2016-08-16
HN2009003002A (en) 2014-03-24
DOP2009000243A (en) 2010-10-31
CR11100A (en) 2010-01-19
ZA200906764B (en) 2010-08-25
JP2010523670A (en) 2010-07-15
IL201284A (en) 2016-06-30
ECSP099724A (en) 2010-03-31
PT2139484E (en) 2013-10-31
NZ580110A (en) 2012-06-29
DK2139484T3 (en) 2013-10-21
JP2014034576A (en) 2014-02-24
ES2430614T3 (en) 2013-11-21
HK1139863A1 (en) 2010-09-30
US20100209420A1 (en) 2010-08-19
EP2139484A1 (en) 2010-01-06
BRPI0810206A2 (en) 2014-10-21
EP2139484B1 (en) 2013-07-17
CO6251254A2 (en) 2011-02-21
WO2008124161A1 (en) 2008-10-16
MA31358B1 (en) 2010-05-03

Similar Documents

Publication Publication Date Title
PL2139484T3 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
PL2483278T3 (en) Benzoxazepin pi3k inhibitor compounds and their use in the treatment of cancer
IL208838A0 (en) Purine pi3k inhibitor compounds and methods of use
EP2211854A4 (en) Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
EP2318406A4 (en) Thiosemicarbazone inhibitor compounds and cancer treatment methods
IL218800A0 (en) Benzoxepin pi3k inhibitor compounds and methods of use
IL219253A (en) Benzodiazepine bromodomain inhibitor for use in the treatment of cancer
IL197315A0 (en) Treatment of cancer
EP2136847A4 (en) Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer
PL2340042T3 (en) Methods and compositions for the treatment of cancer
ZA201006988B (en) Method and compositions for treatment of cancer
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
EP2242501A4 (en) Therapeutic inhibitors of pai-1 function methods of their use
IL199689A0 (en) Compounds and method for treatment of cancer
EP2176406A4 (en) Compositions and methods of treating cancer
PL2187967T3 (en) Methods and compositions for treating cancer
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
EP2225226A4 (en) Compounds and method for treatment of cancer
IL205452A0 (en) Methods of treating scleroderma
IL205339A0 (en) Compounds and methods for the treatment of cancer
IL196361A0 (en) Combination methods of treating cancer
GB0600903D0 (en) Treatment of cancer
ZA200904158B (en) Methods of cancer treatment with IGF1R inhibitors
GB0712513D0 (en) Treatment of cancer
GB0622471D0 (en) Use of reversine and analogs for treatment of cancer